interferon regulatory factor 6
Zuletzt aktualisiert 7 Jul 2022
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Ask Patient
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
The IRF6 gene provides instructions for making a protein that plays an important role in early development. This protein is a transcription factor, which means that it attaches (binds) to specific regions of DNA and helps control the activity of particular genes. The IRF6 protein is active in cells that give rise to tissues in the head and face. It is also involved in the development of other parts of the body, including the skin and genitals.
Normal function
The IRF6 gene provides instructions for making a protein that plays an important role in early development. This protein is a transcription factor, which means that it attaches (binds) to specific regions of DNA and helps control the activity of particular genes. The IRF6 protein is active in cells that give rise to tissues in the head and face. It is also involved in the development of other parts of the body, including the skin and genitals.
Conditions referring to this gene or chromosome
Other names
IRF6_HUMAN
LPS
OFC6
PIT
PPS
VWS
VWS1
Related patient information and medicines

Patient information leaflet
Polycythaemia rubra vera
Polycythaemia rubra vera (PRV) is a myeloproliferative disorder, which means the bone marrow makes too many blood cells. Dr Krishna Vakharia , 24th November 2023 The National Institute for Health and Care Excellence (NICE) has recommended an oral medication called ruxolitinib is for treating polycythaemia vera in adults who cannot tolerate.

Patient information leaflet
Chronische myeloische Leukämie
The chemical tyrosine kinase is made by the abnormal gene BCR-ABL on the Philadelphia chromosome described above. This is thought to be responsible for the abnormal growth and behaviour of the abnormal cells. Imatinib works by blocking the effect of tyrosine kinase. Interferon alfa. This medicine has been shown to help the immune system to combat.

Patient information leaflet
Legionärskrankheit
Human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDs) HIV and AIDs. The effect of medicines which affect the immune system, including: Long-term steroid medication. Chemotherapy for cancer. Immunosuppressant medication, such as azathioprine, mycophenolate, ciclosporin, tacrolimus, rituximab and interferon..

Patient information leaflet
Tuberkulose
A sample of fluid from the stomach (gastric washings) may then be used instead. Other tests Other possible tests for suspected TB are: A blood test called an interferon gamma test. This can be helpful if the tuberculin skin test result was unclear. A 'screening test' for... The tests used for screening are a chest X-ray and/or ein tuberculin test..

Patient information leaflet
Hepatitis B
People with chronic hepatitis B usually need treatment to s... A liver specialist will usually advise on when treatment may be beneficial. There are two types of treatment currently given: Interferon. This medicine is similar to a substance produced in your body, which is also called interferon. It works to fight infections by boosting dein immune.

Patient information leaflet
Leberzirrhose
Leberzirrhose is a serious condition where normal liver tissue is replaced by scar tissue (fibrosis). It tends to progress slowly and often does not cause symptoms in its early stages. However, as the function of the liver gradually becomes worse, serious problems can develop. In the UK, the two commonest causes of cirrhosis are alcohol drinking above.
Weiterführende Lektüre und Referenzen
- interferon regulatory factor 6; MedlinePlus, National Library of Medicine.
- Bailey CM, Abbott DE, Margaryan NV, Khalkhali-Ellis Z, Hendrix MJ. Interferon regulatory factor 6 promotes cell cycle arrest and is regulated by the proteasome in a cell cycle-dependent manner. Mol Cell Biol. 2008 Apr;28(7):2235-43. doi: 10.1128/MCB.01866-07. Epub 2008 Jan 22.
- Kondo S, Schutte BC, Richardson RJ, Bjork BC, Knight AS, Watanabe Y, Howard E, de Lima RL, Daack-Hirsch S, Sander A, McDonald-McGinn DM, Zackai EH, Lammer EJ, Aylsworth AS, Ardinger HH, Lidral AC, Pober BR, Moreno L, Arcos-Burgos M, Valencia C, Houdayer C, Bahuau M, Moretti-Ferreira D, Richieri-Costa A, Dixon MJ, Murray JC. Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes. Nat Genet. 2002 Oct;32(2):285-9. doi: 10.1038/ng985. Epub 2002 Sep 3.
- Mukhopadhyay N, Feingold E, Moreno-Uribe L, Wehby G, Valencia-Ramirez LC, Muneton CPR, Padilla C, Deleyiannis F, Christensen K, Poletta FA, Orioli IM, Hecht JT, Buxo CJ, Butali A, Adeyemo WL, Vieira AR, Shaffer JR, Murray JC, Weinberg SM, Leslie EJ, Marazita ML. Genome-Wide Association Study of Non-syndromic Orofacial Clefts in a Multiethnic Sample of Families and Controls Identifies Novel Regions. Front Cell Dev Biol. 2021 Apr 9;9:621482. doi: 10.3389/fcell.2021.621482. eCollection 2021.
- Park JW, McIntosh I, Hetmanski JB, Jabs EW, Vander Kolk CA, Wu-Chou YH, Chen PK, Chong SS, Yeow V, Jee SH, Park BY, Fallin MD, Ingersoll R, Scott AF, Beaty TH. Association between IRF6 and nonsyndromic cleft lip with or without cleft palate in four populations. Genet Med. 2007 Apr;9(4):219-27. doi: 10.1097/gim.0b013e3180423cca.
- Schutte BC, Saal HM, Goudy S, Leslie EJ. IRF6-Related Disorders. 2003 Oct 30 [updated 2021 Mar 4]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1407/
- Vieira AR, Modesto A, Meira R, Barbosa AR, Lidral AC, Murray JC. Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis. Am J Med Genet A. 2007 Mar 15;143A(6):538-45. doi: 10.1002/ajmg.a.31620.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
7 Jul 2022 | Neueste Version
1 Jul 2022 | Ursprünglich veröffentlicht
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.

